Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

bocodepsin (OKI-179)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

OnKure, Pfizer

Drug class:

HDAC inhibitor

Related drugs:

‹

›

BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	binimetinib + OKI-179 Sensitive: D – Preclinical binimetinib + OKI-179 Sensitive : D	binimetinib + OKI-179 Sensitive: D – Preclinical binimetinib + OKI-179 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	encorafenib + OKI-179 Sensitive: D – Preclinical encorafenib + OKI-179 Sensitive : D	encorafenib + OKI-179 Sensitive: D – Preclinical encorafenib + OKI-179 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib + OKI-179 Sensitive: D – Preclinical binimetinib + OKI-179 Sensitive : D	binimetinib + OKI-179 Sensitive: D – Preclinical binimetinib + OKI-179 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	encorafenib + OKI-179 Sensitive: D – Preclinical encorafenib + OKI-179 Sensitive : D	encorafenib + OKI-179 Sensitive: D – Preclinical encorafenib + OKI-179 Sensitive : D